Pediatrix Medical Group (NYSE:MD) Stock Price Target Raised at Truist Financial

Pediatrix Medical Group (NYSE:MD) had its price objective boosted by Truist Financial from $28.00 to $31.00 in a report released on Friday morning,Benzinga reports. The firm currently has a hold rating on the stock.

Several other equities research analysts have also issued reports on MD. UBS Group increased their target price on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the stock a “neutral” rating in a research note on Thursday, August 6th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $25.00 price target on shares of Pediatrix Medical Group in a research note on Wednesday, August 5th. Wall Street Zen raised Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 13th. Jefferies Financial Group cut Pediatrix Medical Group from a “buy” rating to a “hold” rating and upped their price target for the stock from $27.00 to $28.00 in a report on Wednesday, August 19th. Finally, Weiss Ratings upgraded Pediatrix Medical Group from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, September 9th. One analyst has rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Pediatrix Medical Group has an average rating of “Hold” and a consensus target price of $27.20.

Pediatrix Medical Group Price Performance

Shares of NYSE MD opened at $29.75 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.00 and a quick ratio of 1.32. The stock has a market capitalization of $2.42 billion, a price-to-earnings ratio of 16.17 and a beta of 0.61. The firm’s 50 day simple moving average is $26.93 and its 200-day simple moving average is $23.86. Pediatrix Medical Group has a 12 month low of $16.90 and a 12 month high of $30.55.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Thursday, October 29th. The company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.07. Pediatrix Medical Group had a net margin of 7.66% and a return on equity of 20.12%. The firm had revenue of $501.37 million during the quarter, compared to analysts’ expectations of $498.18 million. During the same period in the previous year, the business posted $0.67 EPS. The business’s revenue was up 1.7% compared to the same quarter last year. Analysts expect that Pediatrix Medical Group will post 2.17 EPS for the current year.

Institutional Trading of Pediatrix Medical Group

Institutional investors and hedge funds have recently modified their holdings of the stock. Global Retirement Partners LLC purchased a new stake in Pediatrix Medical Group during the 2nd quarter valued at about $33,000. Nykredit A S purchased a new position in Pediatrix Medical Group in the 2nd quarter worth approximately $35,000. Signaturefd LLC lifted its stake in Pediatrix Medical Group by 301.8% in the 3rd quarter. Signaturefd LLC now owns 2,013 shares of the company’s stock worth $52,000 after purchasing an additional 1,512 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in Pediatrix Medical Group in the 2nd quarter worth approximately $53,000. Finally, Fortitude Family Office LLC boosted its holdings in shares of Pediatrix Medical Group by 2,239.3% during the 3rd quarter. Fortitude Family Office LLC now owns 2,082 shares of the company’s stock worth $54,000 after purchasing an additional 1,993 shares during the last quarter. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group News Roundup

Here are the key news stories impacting Pediatrix Medical Group this week:

• Positive Sentiment: Pediatrix reported third-quarter adjusted earnings of $0.72 per share, exceeding consensus estimates of $0.63-$0.65 and rising from $0.67 a year earlier. Revenue reached $501.37 million, also above expectations of $498.18 million, while increasing 1.7% year over year. Pediatrix Medical Group Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: Share repurchases helped drive the quarterly EPS beat, providing a favorable signal for per-share earnings and potentially supporting the stock’s valuation. Pediatrix Medical Group Q3 2026 Earnings
• Positive Sentiment: The earnings release showed a 20.05% return on equity and an 8.96% net margin, reinforcing the company’s profitability profile. Pediatrix Medical Group Reports Third-Quarter Results

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc provides specialized physician-led healthcare services for women, infants and children. The company’s clinical offerings include neonatal and perinatal care, maternal-fetal medicine, pediatric medical subspecialties, pediatric hospitalist services and related services delivered in partnership with hospitals and healthcare systems.

Pediatrix-affiliated physicians and advanced practice providers generally work in hospital-based settings, including neonatal intensive care units, delivery rooms, pediatric units and outpatient practices.